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Abstract
Background. Polypharmacy is a main issue of patient safety in all
healthcare settings (i.e. increase adverse drug reactions and incidence
of drug-drug interactions, etc.). The main object of the study was to
evaluate the prevalence of polypharmacy and the appropriateness of
drugs prescriptions in the regional health system (RHS) of Friuli
Venezia-Giulia Region, Italy.
Design and methods. We carried out a point prevalence study in May
2014; 1582 patients ≥65 years were included from: 14 acute hospitals,
46 Long Term Care Facilities (LTCFs) and 42 general practitioners’
(GPs) clinics. Data analysis included the evaluation of potentially
inappropriate prescriptions (PIPs) taking Beers criteria as a reference. 
Results. Patients in therapy with 10 drugs or more were 13.5%: 15.2%
in hospitals, 9.7% in GPs’ clinics and 15.6% in LTCFs. According to Beers
criteria we identified 1152 PIPs that involved globally almost half of
patients (46.0%): 41.9% in hospitals, 59.6% in LTCFs and 37.0% in GP’s
clinics. The 53.9% of patients received at least one mainly kidney excret-
ed drug; for these patients the evaluation of serum creatinine was overall
present in the 87.7% (747/852): 96.4% in hospital ones, 87.5% in GPs’
clinics and 77.8% in LTCFs. LTCFs residents were significantly (P<0.05)
more exposed to PIPs and less monitored for the renal function.
Conclusions. A reliable estimation of the phenomenon in all the
main healthcare settings is a necessary prerequisite to set tailored
policies for facing polypharmacy within a RHS; the results showed the
necessity to put a special attention on LTCFs. 
Introduction
Polypharmacy represents a main patient safety issue in all health-
care settings worldwide.1 Although it can potentially concern people of
any ages, the elderly are most frequently involved: the availability of a
greater number of drugs, the increase of life expectancy and a higher
prevalence of chronic diseases represent the main reasons for a high-
er incidence in this population.2
Many definitions of polypharmacy, both qualitative and quantitative,
are currently used: medication does not match the diagnosis, excessive
use of medication, duplication of medication, medication prescribed to
treat the side effect of another medication,3 but the simultaneous intake
of many medications (generally five or more) is the one more fre-
quently adopted.4-6
The prevalence of polypharmacy in Europe ranges from to 33.8% to
73.3% depending on definition reported;7,8 official data regarding the
prevalence of polypharmacy in Italian elderly (approximately 12 mil-
lion of people ≥65 years old) report that 6 million people were treated
with 5-9 drugs and 1.3 million with 10 drugs or more.9 These data
potentially underestimate the phenomenon because they did not
include medications not reimbursed by the national pharmaceutical
formulary, such as benzodiazepines and some of non-steroidal anti-
inflammatory drugs (NSAIDs).
Possible consequences of polypharmacy include: increase of adverse
drug reactions (ADR), incidence of drug-drug interactions, decrease in
patient compliance to treatment, increase of risk of falling, inability
and cost increase for healthcare system,10-13 due to an higher rate of
hospitalisation, morbidity and mortality.
Although general data are available on polypharmacy, only few ones
are available about its presence in the main healthcare settings: pri-
mary care, LTCFs and hospitals. A detailed picture at healthcare system
level is, in fact, a first step for facing polypharmacy. This paper reports
the results of a multi-setting survey on polypharmacy conducted in a
regional healthcare system with the aim to identify strengths and
weaknesses of the different settings as premise for the definition of
tailored actions.
Design and Methods
The study was carried out in the regional healthcare system (RHS)
of Friuli Venezia Giulia (FVG), Italy, in March 2014 and explored the
three main settings that provide care to elderly: a) all the fourteen pub-
lic and private acute hospitals of the RHS, b) 46 (out of 90) long term
care facilities (LTCFs) (22 nursing homes and 24 long term chronic
care facilities) and c) 42 volunteer general practitioners (GPs) repre-
senting all the 22 local health districts of RHS.
Eligible people were all the 65 years old or more who, at the moment
of the survey, were taking at least one chronic or acute drug. Oncologic
drugs and topical medications (i.e. eye-drops and ointments) were
excluded as well as homeopathic and natural ones. 
The sample was recruited applying a specific approach in each set-
ting: a) for hospitals all the eligible patients discharged from internal
Significance for public health
We believe that our research is appropriate for your journal because con-
cerns a very important issue for healthcare systems: the management of
drugs in elderly people, in particular our study evaluated the topic of
polypharmacy and potentially inappropriate prescriptions in a whole regional
healthcare system, considering the three main care settings: acute hospi-
tals, long term care facilities and general practitioners’ clinics. We also
analysed the problem included all the medications that patients assumed,
not only ones that were reimbursed by healthcare system. Considering these
premises this study permitted to have a wide point of view for setting tai-
lored policies and it underlines the importance of creating a system that
starts from real data and in this way will allows to compare and measure
improvement actions.
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medicine, geriatrics, cardiology and neurology wards in seven consecu-
tive working days; b) for LTCFs, that included two types of facilities dif-
fering by intensity of care and length of stay, we carried out the survey in
a single day and included the 30% (randomly selected) of eligible resi-
dents (from an overall sample of 739 residents) in long-term chronic care
facilities and the 10% in the nursing homes (from an overall sample of
2410 residents). The selected survey index day for LTCFs was the first
one of the survey in hospitals and GPs, this choice was made to avoid the
bias that residents in LTCFs could be re-evaluated during a following
admission in hospital; c) for GPs the sample was composed by the first
two eligible people who accessed to the GPs’ clinics each day for seven
consecutive working days. For each patient we anonymously collected:
age, gender, weight, most recent blood values of creatinine (within a
year), presence of specific chronic diseases, prescribed medication
name, the therapy dose and length. All prescribed medications were col-
lected, also not RHS reimbursed and pro re nata (PRN) therapy. The sur-
vey methodology was preliminary tested in two wards (geriatrics and car-
diology) of two hospitals and in three LTCFs. Moreover a two hours
course to train data collectors was organised by the coordination team
and included all the 60 professionals involved in the survey.
Data were collected by reviewing medical records for hospitalised
patients and LTCFs residents; for outpatients all necessary information
was provided by the GPs through their electronic databases.
Medications were classified following the Anatomical Therapeutic
Chemical (ATC). On the basis of available literature on topic,4-6 exposi-
tion to medications was stratified into three classes: from 1 to 4, from
5 to 9 (polypharmacy) and 10 or more (hyper-polypharmacy).
We also analysed the presence of potentially inappropriate prescrip-
tion (PIP) defined using the 2012 Beers Criteria.14
The study protocol was approved by the Regional Ethical Committee
in March 2014. 
Categorical variables were compared using Shapiro-Wilk test for
evaluating normality, Pearson test for linear correlation, Kruskal-Wallis
test for non-parametric data and logistic regression model. We accept-
ed a P<0.05 as a significant value.
All data analysis was performed using IBM SPSS Statistics 20. 
Results
The survey involved overall 1582 patients; their characteristics, strat-
ified by setting, are summarised in Table 1.
The mean±SD age of the study population was 80.5±8.4, with a sig-
nificant variability (P<0.05) by setting: hospitals 80.8±8.1, GPs
76.7±7.8 and LTCFs 84.1±7.8. Females were the majority 54.7%
(323/591) and 74.9% (420/561) respectively in the 75-84 and in the 85
or more classes of age, while males were the majority in the 65-74 class
55.6% (239/430). Almost all patients (96.4%) suffered at least of one
disease with a mean ±SD of 3.4±1.5 diseases for patients (range from
0 to 12): hospitals 3.2±1.8, GPs 3.1±2.0 and LTCFs 3.2±1.7.
Hypertension resulted the most common reported chronic disease
60.2% (953/1582), followed by arrhythmic disorders 27.7% (438/1582),
heart diseases 25.9% (410/1582), diabetes mellitus 25.8% (408/1582),
arthropathy 25.5% (403/1582) and cerebro-vascular artery disease
25.3% (400/1582). The most common associations resulted: hyperten-
sion and diabetes mellitus 17.9% (283/1582), hypertension and
arrhythmic disorders 17.6% (278/1582) and hypertension and heart dis-
eases 17.2% (272/1582).
The mean ±SD number of prescribed drugs for each patient resulted
6.1±3.0.The mean number was significantly lower (P<0.05) for GPs’
outpatients (5.5±3.0) than for hospitalised patients (6.4±2.9) and
LTCFs residents (6.3±2.9). There was a moderate significant linear
correlation (P<0.05) between the numbers of diseases and number of
drugs assumed (Pearson’s test 0.37).
Cardiovascular system (36.3%, 3485 out of 9599), alimentary tract
and metabolism (20.0%, 1923 out of 9599) and blood and blood forming
organs (14.9%, 1427 out of 9599) were the three ATC drugs categories
most frequently prescribed; Table 2 specifies the five most common
ATC classes for each setting.
We observed that 53.9% (852/1582) of patients received at least one
mainly kidney excreted drug (ramipril, metformin, allopurinol, digoxin,
enalapril, nebivolol, levofloxacin, atenolol, levetiracetam and prega-
balin); for these patients the evaluation of serum creatinine (neces-
sary for estimating renal function) was overall present in the 87.7%
(747/852), with significant difference in the three settings (P<0.05):
96.4% (295/306) in hospital ones, 87.5% (245/280) in GPs’ clinics and
77.8% (207/266)  in LTCFs.
According to Beers criteria we found 1152 PIPs that involved almost
half of patients (46.0%, 728 out of 1582): 41.9% (219/528) in hospitals,
59.6% (314/527) in LTCFs and 37.0% (195/527) in GP’s clinics; Table 3
shows the univariate analysis and the logistic regression model for the
presence of at least one PIP. 
All 1582 patients were included in the logistic regression model and
we evaluated the parameters that resulted statistically significant
(P<0.05) in the univariate analysis. Results highlight that the risk of
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Table 1. Studied population characteristics by explored setting.
                                                  Hospitals (n. 528)                  GPs (n. 527)                        LTCFs (n. 527)                 Overall (n. 1582)
                                                            n. (%)                                 n. (%)                                     n. (%)                                  n. (%)
Females                                                             261 (49.3)                                       302 (57.3)                                           371 (70.4)                                       934 (59.0)
Age classes                                                                                                                                                                                                                                                
          65-74                                                         128 (24.2)                                       233 (44.2)                                            69 (13.1)                                        430 (27.2)
          75-84                                                         205 (38.8)                                       203 (38.5)                                           183 (34.7)                                       591 (37.4)
          ≥85                                                           195 (36.9)                                        91 (17.3)                                            275 (52.2)                                       561 (35.5)
N. of prescribed drugs                                                                                                                                                                                                                            
          1-4                                                             139 (26.3)                                       223 (42.3)                                           157 (29.8)                                       519 (32.8)
          5-9                                                            309 (58.5)                                       253 (48.0)                                           288 (54.6)                                       850 (53.7)
          ≥10                                                            80 (15.2)                                          51 (9.7)                                              82 (15.6)                                        213 (13.5)
Number of diseases                                                                                                                                                                                                                                
          0-1                                                              80 (15.2)                                          51 (9.7)                                              83 (15.7)                                        214 (13.5)
          2-4                                                             317 (60.0)                                       300 (56.9)                                           342 (64.9)                                       959 (60.6)
          ≥5                                                             131 (24.8)                                       176 (33.4)                                           102 (19.4)                                       409 (25.9)
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PIP increases with the number of assumed drugs (OR 2.77 and 5.60
respectively for 5-9 class and ≥10 class compare to 1-4); also the setting
has an important influence, in fact hospital and GPs’ patients have a
significantly lower risk (OR 0.46 for both) compared to elderly people
in LTCFs.
Discussion and Conclusions
The study was carried out to obtain an overall picture of medications
use in elderly people for the different RHS settings; sample heterogene-
ity was a necessary requisite to understand the problem in all its com-
plexity; the three involved settings represent the main care providers
for elderly in the RHS so a specific knowledge of their situation was
considered an essential prerequisite for the definition and implemen-
tation of actions and setting policies. 
In this perspective, the prevalence survey was the methodology for
reaching our goal; it allowed us both to recruit many patients in a lim-
ited time and to collect all the prescribed drugs (included RHS not
reimbursed and PRN ones), two requisites necessary for a thorough
picture as close as possible to reality. Furthermore this approach was
able to overcome the existing differences in the way clinical data are
reported, collected and stored in the 3 different settings and within
                                Article
Table 2. The five most common prescribed drug classes stratified by setting.
Hospitals (n. 3386)                                                       General practitioners (n. 2872)                        LTCFs (n. 3341)
Drug class                                       n.            %              Drug class                          n.            %                Drug class                        n.        %
B01 Antithrombotic agents                        481             14.2                C09 Agents acting on                  374            13.0                  B01 Antithrombotic                 425       12.7
                                                                                                                   the renin-angiotensin system                                              agents                                            
A02 Drugs for acid related disorders     379             11.2                B01 Antithrombotic agents       330            11.5                  A02 Drugs for acid                  380       11.4
                                                                                                                                                                                                                       related disorders                       
C03 Diuretics                                                315              9.3                 C10 Lipid modifying agents       222             7.7                   N05 Psycholeptics                    284        8.5
C09 Agents acting on the                           267              7.9                 A02 Drugs for acid related       214             7.5                   C03 Diuretics                            251        7.5
renin-angiotensin system                                                                    disorders
C07 Beta blocking agents                           243              7.2                 C07 Beta blocking agents          191             6.7                   C09 Agents acting                    211        6.3
                                                                                                                                                                                                                       on the renin-angiotensin 
                                                                                                                                                                                                                       system                                           
Table 3. Logistic regression model and univariate analysis of the presence of at least one potentially inappropriate medication (PIP) for
Beers criteria.
                                  Presence of at least one PIP                              Univariate analysis                                      Logistic regression
                    Patients exposed      Patients not exposed                                      
                                                                                                        Sig.                OR             95% CI                      Sig.             OR           95% CI
Gender                                                                                                                         0.02                    1.26                1.03-1.55                             0.08                1.22             0.97- 1.53
       Female                     452                                            482                                                                                                                                                                
       Male                          276                                            372                                                                                                                                                                
Age class                                                                                                                      0.00                    1.52                1.18-1.95                             0.26                1.19              0.90-1.56
       75-84                          284                                            307                                                                                                                                                                
       65-74                          163                                            267                                                                                                                                                                
Age class                                                                                                                      0.00                    1.64                1.27-2.12                             0.47                1.12              0.83-1.50
       ≥85                            281                                            280                                                                                                                                                                
       65-74                          163                                            267                                                                                                                                                                
Setting                                                                                                                          0.00                    0.48                0.38-0.62                             0.00                0.46              0.35-0.60
       Hospitals                  219                                            309                                                                                                                                                                
       LTCFs                        314                                            213                                                                                                                                                                
Setting                                                                                                                          0.00                    0.40                0.31-0.51                             0.00                0.46              0.35-0.60
       GPs                            195                                            332                                                                                                                                                                
       LTCFs                        314                                            213                                                                                                                                                                
Diseases                                                                                                                       0.04                    1.56                1.15-2.12                             0.16                1.26              0.91-1.76
       2-4                              448                                            511                                                                                                                                                                
       0-1                               77                                             137                                                                                                                                                                
Diseases                                                                                                                       0.01                    1.75                1.25-2.46                             0.33                1.21              0.83-1.76
       ≥5                              203                                            206                                                                                                                                                                
       0-1                               77                                             137                                                                                                                                                                
Prescribed drugs                                                                                                       0.00                    2.81                2.22-3.55                             0.00                2.77              2.16-3.54
       5-9                              439                                            411                                                                                                                                                                
       1-4                              143                                            376                                                                                                                                                                
Prescribed drugs                                                                                                       0.00                    5.73                4.05-8.11                             0.00                5.60              3.87-8.12
       ≥10                            146                                             67                                                                                                                                                                 
       1-4                              143                                            376
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each setting. The sample recruitment was set with different method-
ologies in the three settings adopting a tailored strategy for the differ-
ent characteristics of patients’ stay: acute ones, residents and outpa-
tients.
The overall prevalence of polypharmacy (67.2%) was quite similar to
the results (61.0%) of the national prevalence study conducted by
Geriatric Working Group of Italian Agency of Drugs (AIFA) in 2011;15
the gap between the two scenarios could be explained by the absence
of the not reimbursed drugs by national pharmaceutical formulary in
the AIFA one. Reliability of our data can also be confirmed by the
increase in number of chronic diseases correlated to the number of
prescribed drugs, as highlighted in literature.16,17
Taking Beers criteria as reference,14 the survey revealed that approx-
imately half of patients (46.0%) had at least one PIP in their therapy,
substantially similar to the results of other available experiences which
analysed only single settings.18,19 In our case, the analysis by setting
allowed a comparison and LTCFs emerged as most critical: almost 6
patients out of 10 presented a PIP. This result was significantly higher
(P<0.05) compared to the other settings, also considering that the
majority of LTCFs residents were followed by their own GPs and that in
LTCFs the prevalence of 5 or more diseases was lower compared to GPs’
outpatients.
Furthermore through this approach we found that one of the main
causes of PIPs occurrence was the significant (P<0.05) higher use of
psycholeptic drugs in LTCFs compared to the other two settings.
Also data regarding the evaluation of renal function for patients who
were taking at least one drug with renal excretion confirmed that
LTCFs had a lower level of compliance compared to the other two set-
tings; this is an important issue for patient safety because the knowl-
edge of renal function is necessary to adapt drugs doses and to prevent
accumulation complications.
The study identified a problem that must be necessarily considered
primary for patient safety in a context of regional risk management
approach, the stewardship of long term care providers for elderly also
considering the emerging change in population demography. 
A strength of the proposed approach is the ability to provide a full
view of the state of the art about drugs prescription quality in a RHS; it
could potentially be a starting point for policies aimed to improve
patient safety and safer drug use: based on these results it is possible
to communicate the state of the art to all interested stakeholders and
to set tailored improvement programmes. Although there are many
papers describing polypharmacy in elderly population almost all of
them explored only one care setting and did not included systematically
all prescribed drugs. 
Regional plans should consider educational programmes for pre-
scribers, continuous data flow on drugs use to all healthcare practition-
ers, sharing of good practices about drugs management (i.e. the peri-
odic re-evaluation of patient’s therapy, the careful check of possible
drug-drug interaction and of potentially inappropriate medications,
etc.) and patient literacy on drugs use;20,21 further medication reconcil-
iation should be systematically applied in all the healthcare settings
and with particular attention in LTCFs, as they showed the greatest
polypharmacy concern. 
The routinely evaluation of renal function in elderly patients taking
mainly kidney excreted drugs is one of the most important, and possi-
bly less expensive, improvement initiatives suggested by our findings
and it will be a priority for ensuring the right dose of drugs in this way
preventing accumulation.
These data as well as their periodical repetition could be very helpful
both in making clear different aspects of the problem locally and mon-
itoring possible progresses. 
The proposed approach had also some limitations and particularly,
first one was that GPs’ recruitment for outpatients was only possible on
voluntary basis and it consequently could had selected the more moti-
vated ones; another one was that GPs’ outpatients, in spite of presence
of higher prevalence of diseases, were usually more independent for
own care management compared to LTCFs ones. Furthermore the adop-
tion of only the Beers criteria could have underestimated PIPs rate if
compared with studies that utilised also Screening Tool of Older
Persons’ Potentially inappropriate Prescriptions (STOPP),22,23 but for
our aim it was more important adopting an unique standardised tool
that allows us to compare the three settings.
In conclusion, the availability of reliable estimation of the phenom-
enon in all the main healthcare settings of RHS is a necessary pre-req-
uisite for setting up effective policies aimed to control polypharmacy. In
our context LTCFs seemed to need special attention compared to hos-
pitals and GPs’ clinics. The definition of policies and programmes at
health system level needs a periodical monitoring of polypharmacy in
the main settings of the system (primary care, LTCFs and hospitals)
and setting tailored interventions for improving and promoting medica-
tion reconciliation process and drug management.
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